PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

Clinical trial NCT06206096 · UNKNOWN

Trial details

NCT number: NCT06206096
Sponsor: Chinese PLA General Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Cancer RAS Mutation Colorectal Neoplasms Microsatellite Stable Colorectal Carcinoma

Start date: 2021-05-26
Primary completion: 2024-12-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.